Simvastatin was found to inhibit EGFR, fibroblast growth factor receptor (FGFR) and proto-oncogene tyrosine-kinase Src (c-SRC) [77], TKs that are highly active in GBM. This evidence concerns the gene EGFR and glioblastoma.